CClinicalTrials.gg
CompletedNCT04807205Updated Jun 12, 2024Results posted

Post Market Study Using The Elite IQ Device

An interventional study of RF Non-Invasive Treatment in Hair Removal, Pseudo Folliculitis Barbae and Benign Vascular Lesion, sponsored by Cynosure, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Cynosure, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective, open label, single-center clinical study to collect safety and efficacy data on the Elite iQ workstation. The intended use of the Elite iQ device used in this study is for the treatment of hair removal, pseudo folliculitis barbae, and benign vascular and pigmented lesions.

Read the detailed description

Up to 20 subjects will be enrolled at up to 1 study center. Subjects will attend a screening/pretreatment visit which may be performed on the same day as the treatment visit. Subjects may receive up to 5 treatments on multiple areas of the body such as, but not limited to, the face, legs, and arms. All subjects will be required to return a follow-up visit at 30 - 90 days after the final treatment in each treatment area.

02

Conditions studied

  • Hair Removal
  • Pseudo Folliculitis Barbae
  • Benign Vascular Lesion
  • Pigmented Lesions
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • A healthy male or female 18 years of age or older.
  • Understands and accepts obligation not to receive any other procedures on the treatment area through the length of the study.
  • Understands and accepts the obligation and is logistically able to be present for all visits.
  • Is willing to comply with all requirements of the study and sign the informed consent document.

Exclusion criteria

Exclusion Criteria:

  • The subject is hypersensitive to light in the near infrared wavelength region
  • The subject has sun-damaged skin (treatment contraindicated with Alex laser only)
  • The subject had recent unprotected sun exposure (for Alex laser within four weeks of treatment; for Nd:YAG laser within one week of treatment), including the use of tanning beds or tanning products, such as creams, lotions and sprays
  • The subject is taking medication which is known to increase sensitivity to sunlight
  • The subject has seizure disorders triggered by light
  • The subject is taking anticoagulants
  • The subject is taking or have taken oral isotretinoin, such as Accutane®, within the last six months
  • The subject is taking medication that alters the wound-healing response
  • The subject has a history of healing problems or history of keloid formation
  • The subject has an active localized or systemic infection, or an open wound in area being treated
  • The subject has a significant systemic illness or an illness localized in area being treated
  • The subject has a history of skin cancer or suspicious lesions
  • The subject has an autoimmune disease
  • The subject is receiving or have received gold therapy
  • The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within in the area to be treated 6 months to entering this study.
  • The subject has any condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Elite IQ Laser

    The Elite IQ will be used on multiple areas of the body such as, but not limited to, the face, legs, and arms.

    Device: RF Non-Invasive Treatment

Interventions

  • DeviceRF Non-Invasive Treatment

    Self-controlled single-arm group using the Elite IQ device

05

What researchers measure

Primary outcomes

  1. Blinded Evaluation of Pre-treatment Images vs. Follow up Images to Determine Which Image Was Taken Pre-treatment vs. at the Follow up.

    Blind identification of pre-treatment images vs. 60 day follow up images. It is performed by independent reviewers. The outcome will be reported as a percentage of photographs identified correctly.

    Time frame: 60 day (+/- 30 days) post last treatment

Secondary outcomes

  1. Principle Investigator Assessment Using the Global Aesthetic Improvement Scale (PGAIS)

    Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS) at the 60 day follow up visit. The GAIS scale ranges from 1 to 5, with 1 being "very much improved," 2 being "much improved," 3 being "improved," 4 being "no change," and 5 being "worse." This is the count of the number of subjects who the physician graded a 3 or higher.

    Time frame: 60 day (+/- 30 days) post last treatment

  2. Subject Satisfaction

    Subject satisfaction rates at the 60 day follow up visit. The subject satisfaction scale ranges from 1 to 6, with 1 being extremely unsatisfied, 2 being dissatisfied, 3 being slightly unsatisfied, 4 being slightly satisfied, 5 being satisfied, and 6 being extremely satisfied. This is the count of the number of subjects who graded themselves a 4 or higher.

    Time frame: 60 day (+/- 30 days) post last treatment

06

Results

Posted Jun 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneElite IQ Laser
Started20
Completed20
Not completed0

Outcome measures

PrimaryBlinded Evaluation of Pre-treatment Images vs. Follow up Images to Determine Which Image Was Taken Pre-treatment vs. at the Follow up.

Blind identification of pre-treatment images vs. 60 day follow up images. It is performed by independent reviewers. The outcome will be reported as a percentage of photographs identified correctly.

Time frame:
60 day (+/- 30 days) post last treatment
Reported as:
Mean · % of photos correctly identified
Blinded Evaluation of Pre-treatment Images vs. Follow up Images to Determine Which Image Was Taken Pre-treatment vs. at the Follow up.
% of photos correctly identifiedElite IQ Laser
Blinded Evaluation of Pre-treatment Images vs. Follow up Images to Determine Which Image Was Taken Pre-treatment vs. at the Follow up.94.2 ± .05
SecondaryPrinciple Investigator Assessment Using the Global Aesthetic Improvement Scale (PGAIS)

Principle Investigator assessment using the Global Aesthetic Improvement Scale (PGAIS) at the 60 day follow up visit. The GAIS scale ranges from 1 to 5, with 1 being "very much improved," 2 being "much improved," 3 being "improved," 4 being "no change," and 5 being "worse." This is the count of the number of subjects who the physician graded a 3 or higher.

Time frame:
60 day (+/- 30 days) post last treatment
Reported as:
Count of participants · Participants
Principle Investigator Assessment Using the Global Aesthetic Improvement Scale (PGAIS)
ParticipantsElite IQ Laser
Principle Investigator Assessment Using the Global Aesthetic Improvement Scale (PGAIS)20
SecondarySubject Satisfaction

Subject satisfaction rates at the 60 day follow up visit. The subject satisfaction scale ranges from 1 to 6, with 1 being extremely unsatisfied, 2 being dissatisfied, 3 being slightly unsatisfied, 4 being slightly satisfied, 5 being satisfied, and 6 being extremely satisfied. This is the count of the number of subjects who graded themselves a 4 or higher.

Time frame:
60 day (+/- 30 days) post last treatment
Reported as:
Count of participants · Participants
Subject Satisfaction
ParticipantsElite IQ Laser
Subject Satisfaction20

Adverse events

Collected over All adverse events were collected and resolved during the time period of when the study started to the final follow up date (6 months post last treatment, up to a total of 9 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Elite IQ Laser0/20 (0%)0/20 (0%)20/20 (100%)
Most frequent other events
Most frequent other events
EventElite IQ Laser
EdemaSkin and subcutaneous tissue disorders20/20
ErythemaSkin and subcutaneous tissue disorders20/20
CrustingSkin and subcutaneous tissue disorders4/20
BlisteringSkin and subcutaneous tissue disorders2/20
HyperpigmentationSkin and subcutaneous tissue disorders1/20
HypopigmentationSkin and subcutaneous tissue disorders1/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Elite IQ Laser
<=18 years0
Between 18 and 65 years16
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Elite IQ Laser
Female17
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Elite IQ Laser
Caucasian14
Hispanic3
Asian2
African American1
FitzPatrick Skin Type
FitzPatrick Skin Type(Participants)Elite IQ Laser
Fitzpatrick Skin Type I0
Fitzpatrick Skin Type II7
Fitzpatrick Skin Type III8
Fitzpatrick Skin Type IV2
Fitzpatrick Skin Type V2
Fitzpatrick Skin Type VI1
07

Study locations

1 site
  • Scripps Clinic Carmel Valley
    San Diego, California 92130, United States
08

References and documents

Publications

  • Gupta V, Sharma VK. Skin typing: Fitzpatrick grading and others. Clin Dermatol. 2019 Sep-Oct;37(5):430-436. doi: 10.1016/j.clindermatol.2019.07.010. Epub 2019 Jul 17. PubMed 31896400 ↗

Study documents

  • Protocol and statistical analysis plan · Oct 30, 2020

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT04807205
Lead sponsor
Cynosure, Inc.
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
Mar 26, 2021
Primary completion
Mar 2, 2022
Completion
Mar 2, 2022
Results posted
Jun 15, 2023
Last update
Jun 12, 2024

Study contacts

Jennifer Civiok
study director · Cynosure, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion